Skip to content
Markets News
Earnings1 min read

AstraZeneca profit rises 23% as cancer sales lift quarterly results

Makkler Newsroom
October 30, 2026 · Based on reporting by finanzen.net, Euronews

The drugmaker reported higher third-quarter revenue and profit, and plans annual savings of $1.5 billion for reinvestment in its business.

Key takeaways

  • Third-quarter profit after tax increased 23% to $3.12 billion.
  • Oncology sales rose 17% to $7.8 billion.
  • AstraZeneca plans $1.5 billion in annual savings, mainly for reinvestment.

AstraZeneca’s profit after tax rose 23% to $3.12 billion in the third quarter, as sales of cancer medicines helped drive revenue up 7% to $16.2 billion. The company also announced a plan to deliver $1.5 billion in annual savings.

Oncology sales increased 17% to $7.8 billion, accounting for 48% of revenue. AstraZeneca said Tagrisso and Imfinzi led growth in the division. Core earnings per share rose 17% to $2.79.

The savings plan will incur up to $2 billion in one-off restructuring charges and is due to be largely complete by the end of 2029. AstraZeneca said it intends to reinvest the savings, mainly in its drug development pipeline. It has not announced job cuts.

Sales of Farxiga fell 25% to $1.6 billion after cheaper generic versions entered the US market. The company also cited pressure from China’s bulk-buying scheme. AstraZeneca confirmed its 2026 outlook, forecasting mid-to-high single-digit revenue growth and low double-digit growth in core earnings per share, excluding currency movements.

As of 14:49 UTC on Friday, AstraZeneca shares traded at 13,824 pence, up 5.91% from the previous close.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.